True precision medicine through single-cell science
Scailyte has raised $1.8M in total funding. The most recent round was Series A. The last funding was announced in December 2023.
Scailyte's investors include Verve Ventures, Swisscom Ventures, MassChallenge, Venture Kick, Innosuisse.
Scailyte is headquartered in Basel, Switzerland.
True precision medicine through single-cell science
Scailyte is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Scailyte — Funding & Investors." VCBacked, December 4, 2023, https://www.vcbacked.co/company/scailyte. Accessed July 19, 2026.
VCBacked. (2023). Scailyte — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/scailyte
{{cite web |title=Scailyte — Funding & Investors |url=https://www.vcbacked.co/company/scailyte |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated